Grant: Team Grant: Vision, Hearing and Communication Disorders - LOI
University of Alberta
$5,000.00
CIHR Team in Vision [Glaucoma - from genetics to therapy]
EF 2009-10
Résumé
Glaucoma is a complex trait with a substantial genetic basis and to date genes accounting for ~15% of cases have been defined. Treatment for this heterogeneous group of optic nerve disorders has, however, not kept pace with these advances, still relying upon an approach (lowering intraocular pressure) developed more than a century ago. Failure of current treatments to target disease mechanisms result in chronic disability, with major negative effects on quality of life. To address this and apply understanding of the molecular basis of glaucoma into clinical practice, we are establishing a multi-disciplinary team to identify novel glaucoma-causing genes, and especially those variants predisposing to blindness. Combined with targeted molecular diagnostic testing and other clinical translation approaches, these will represent important strategies for improving visual health.
Programme
Team Grant: Vision, Hearing and Communication Disorders - LOI
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
185661
Name
Lehmann Ordan J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Team Grant: Vision, Hearing and Communications Disorders
Projecttitle
CIHR Team in Vision [Glaucoma - from genetics to therapy]
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$5,000
Cihrequipment2
$0
Programname2
Team Grant: Vision, Hearing and Communication Disorders - LOI
Keyworddelim
Genetics; Glaucoma; Knowledge Translation; Model Organisms
Abstract
Glaucoma is a complex trait with a substantial genetic basis and to date genes accounting for ~15% of cases have been defined. Treatment for this heterogeneous group of optic nerve disorders has, however, not kept pace with these advances, still relying upon an approach (lowering intraocular pressure) developed more than a century ago. Failure of current treatments to target disease mechanisms result in chronic disability, with major negative effects on quality of life. To address this and apply understanding of the molecular basis of glaucoma into clinical practice, we are establishing a multi-disciplinary team to identify novel glaucoma-causing genes, and especially those variants predisposing to blindness. Combined with targeted molecular diagnostic testing and other clinical translation approaches, these will represent important strategies for improving visual health.
Competitiondate
200904
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lehmann, Ordan J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $5,000~ $0~